Acetylation Stabilizes Phosphoglycerate Dehydrogenase by Disrupting the Interaction of E3 Ligase RNF5 to Promote Breast Tumorigenesis

• DOI: 10.1016/j.celrep.2020.108021
• Publication Date: 2020-08-11T14:45:51Z
• Authors: Chao Wang; Xingyou Wan; Tong Yu; Zhenyu Huang; Chao Shen; Qian Qi; Sheng Xiang; Xinyuan Chen; Eyal Arbely; Zhi-Qiang Ling; Chen-Ying Liu; Wei Yu
• Keywords: Male; 0303 health sciences; QH301-705.5; Carcinogenesis; Protein Stability; Ubiquitin-Protein Ligases; Mice, Nude; Acetylation; Breast Neoplasms; Middle Aged; Lysine Acetyltransferase 5; 3. Good health; DNA-Binding Proteins; Mice; 03 medical and health sciences; HEK293 Cells; Sirtuin 2; Cell Line, Tumor; Animals; Heterografts; Humans; Female; Biology (General); Phosphoglycerate Dehydrogenase

Phosphoglycerate dehydrogenase (PHGDH) is the first enzyme in the serine synthesis pathway in which it is also the rate-limiting enzyme. It is significantly upregulated in many cancers, especially breast cancer. However, the posttranslational mechanism of PHGDH upregulation in breast cancer is unknown. In this study, we find that RNF5, an E3 ubiquitin ligase, is essential for the degradation of PHGDH protein. PHGDH is degraded by RNF5 to prevent the proliferation of breast cancer cells. The acetylation of PHGDH at K58 is able to disrupt the interaction of RNF5-PHGDH and promote the proliferation of breast cancer cells. Tip60 and SIRT2 regulate the reversible acetylation modification of PHGDH in response to glucose alteration. Moreover, PHGDH is significantly upregulated in samples of human breast cancer and is associated with decreased RNF5 expression. This implies a potential therapeutic target through the interference interaction of PHGDH-RNF5 to degrade PHGDH in breast cancer.